JS238

JS238 is a newly designed small molecule antibiotic potentiator (adjuvant) developed by researchers at the Université catholique de Louvain and Aix-Marseille University. It is designed to combat multidrug-resistant Gram-negative pathogens, specifically *Pseudomonas aeruginosa*. JS238 acts primarily by disrupting the bacterial outer membrane barrier, increasing membrane fluidity and permeabilization, which facilitates the entry of various classes of antibiotics (including poorly permeable drugs) into the bacterial cell. Preclinical evaluations demonstrate that JS238 significantly reduces the minimum inhibitory concentrations (MICs) of multiple antibiotic classes against both reference and clinical *P. aeruginosa* strains, including efflux-deficient and efflux-overexpressing strains, while maintaining a favorable safety profile with minimal eukaryotic cytotoxicity and hemolysis.